2014年上半年国内22城市(地区)样本医院用药分析  

A comprehensive survey of medication in domestic 22 area sample hospitals in the first half of 2014

作　　者：徐培红[1] 干荣富 

机构地区：[1]上海交通大学医学院附属瑞金医院药剂科,上海200025 [2]国药控股股份有限公司,上海200051

出　　处：《世界临床药物》2014年第11期I0018-I0023,共6页World Clinical Drug

摘　　要：本文分析了国内22城市(地区)样本医院用药数据,发现,近三年样本医院购入药品总金额增幅继续保持在12%左右,整个医院市场趋于平稳;抗感染药物目前已进入常态化管理,已从负增长的困境中走出,该大类药物在样本医院中所占份额不容忽视;供应医院领先厂商中进口、合资企业较本土企业稍占优势,提示,二三级医院对药品的临床使用效果或药品的来源及质量相当重视。In this review, a comprehensive analysis is made based on the drug-use data of domestic 22 area sample hospitals. The conclusion shows that the gross amount of drug purchase in sample hospitals maintains a growth rate of about 12% in recent 3 years. The whole hospital drug-use market is stable. The anti-infective drug has been turned into a normal management and has come out from the negative growth dilemma. According to the sales of leading manufacturing companies in this market, Multinational corporations and joint venture enterprises take a little advantage compared with the local ones. It shows that the clinical efficacy and drug quality are very important issues for the drug sources in hospitals.

关 键 词：医院用药 政策影响 领先品种 领先厂商 

分 类 号：R951[医药卫生—药学]